Otsuka Pharmaceutical Co., Ltd.

Two of them are now on the market.

One from Otsuka is an April only.

That one came out called Voice Act a few months ago, off to a good start.

And then we have Vera Therapeutics just came out with one called Chutakna, also another great name.

So the next steps depend on securing US non-dilutive funding.

Where does SVN 114 sit in your priorities? And with Otsuka's acquisition of Transcend and Resilience MDA resubmission and advancing Comp360 in PTSD, would other therapies reaching the market first be validation or threat?

They would be, let's take that in reverse order, they would be validation, they would establish the marketplace, they would establish the distribution and the treatment paradigm.

I believe there will be challenges with those traditional long tail psychedelics, psychedelic assisted therapy from a healthcare unit economics basis on real estate, on staffing and on costs.

They're for the company's specific medical grade formulations of them and treatment schedules and stuff like that.

In late March of this year, about a month before the executive order, Japanese pharma giant Otsuka Pharmaceutical, with approximately a $40 billion market cap, announced it had entered into an agreement to purchase Transcend for 700 million up front, plus 525 million additional based on certain development milestones being met.

This deal was finally inked in June.

So 1.225 billion?

No use, broadcast, or recording of this presentation or any part thereof is permitted without the written authorization of Medscape.

The following presentation is part of a certified educational activity provided by Medscape Education and supported by an independent educational grant from Otsuka.

[soft music] This program is presented by Medscape Education Global.

Hello, and welcome to this educational activity entitled Navigating IgA Nephropathy Management in an Evolving Treatment Landscape, and boy, is it evolving, um, Key Considerations for Treatment Selection.

the idea.

Um, and so that was Otsuka.

They had the CT-152.

So I think they named the devices based on, like, what version, uh, of the software that they're putting through, and that one was for, um, MDD, right? Major depressive disorder.

I think it was a DMT derivative, which is interesting.

Um, we saw, uh, Otsuka Pharmaceuticals bought TransCend's, uh, methylone, I think it was, or meth- I think it was methylone.

So, which is like, I-

[laughs]